ReviewDer Internist2020
[Pathology of liver tumors].
Review in Der Internist, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Value of intravoxel incoherent motion and diffusion kurtosis imaging to differentiate hepatocellular carcinoma and intrahepatic cholangiocarcinoma.World journal of gastrointestinal oncology · 2025Article
- Clinical benefits of MRI-guided freehand biopsy of small focal liver lesions in comparison to CT guidance.European radiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Based on recent advances in morphological and molecular research, tissue-based diagnostics of liver tumors exhibit a substantial dynamic. New clinically relevant tumor subtypes have been defined and the diagnostic criteria have been improved; examples are the new morphomolecular classifications of hepatocellular carcinoma and adenoma as well as intrahepatic cholangiocarcinoma. Therefore, molecular pathological diagnostics are gaining relevance in the identification of tumor types and therapeutic stratification. These developments are reflected in the new World Health Organization (WHO) classification of hepatobiliary tumors and the respective clinical practice guidelines.
Indexed as
Identifiers
31953548What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.